Mouse Tumor Models for Advanced Cancer Immunotherapy.
CAR T-cell therapy
cancer immunotherapy
cancer mouse models
immune checkpoint inhibitors
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Jun 2020
09 Jun 2020
Historique:
received:
26
05
2020
revised:
04
06
2020
accepted:
06
06
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
26
3
2021
Statut:
epublish
Résumé
Recent advances in the development of new methods of cancer immunotherapy require the production of complex cancer animal models that reliably reflect the complexity of the tumor and its microenvironment. Mice are good animals to create tumor models because they are low cost, have a short reproductive cycle, exhibit high tumor growth rates, and can be easily genetically modified. However, the obvious problem of these models is the high failure rate observed in human clinical trials after promising results obtained in mouse models. In order to increase the reliability of the results obtained in mice, the tumor model should reflect the heterogeneity of the tumor, contain components of the tumor microenvironment, in particular immune cells, to which the action of immunotherapeutic drugs are directed. This review discusses the current immunocompetent and immunocompromised mouse models of human tumors that are used to evaluate the effectiveness of immunotherapeutic agents, in particular chimeric antigen receptor (CAR) T-cells and immune checkpoint inhibitors.
Identifiants
pubmed: 32526987
pii: ijms21114118
doi: 10.3390/ijms21114118
pmc: PMC7312663
pii:
doi:
Substances chimiques
Carcinogens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Russian Foundation for Basic Research
ID : 18-34-00738
Références
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Methods Mol Biol. 2016;1464:129-137
pubmed: 27858362
Science. 1997 Oct 3;278(5335):120-3
pubmed: 9311916
Cells. 2019 Aug 13;8(8):
pubmed: 31412684
Nat Rev Drug Discov. 2013 Aug;12(8):569
pubmed: 23903212
Nature. 1992 Mar 19;356(6366):215-21
pubmed: 1552940
Cancers (Basel). 2019 Feb 19;11(2):
pubmed: 30791458
PLoS One. 2012;7(8):e44219
pubmed: 22937164
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
J Immunother Cancer. 2019 Nov 28;7(1):328
pubmed: 31779705
PLoS One. 2018 Nov 2;13(11):e0206223
pubmed: 30388137
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Oncotarget. 2016 Jun 7;7(23):34341-55
pubmed: 27145284
Stem Cells. 2015 Jun;33(6):1696-704
pubmed: 25694194
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancers (Basel). 2020 Jan 03;12(1):
pubmed: 31947775
J Immunol. 2014 Apr 15;192(8):3654-65
pubmed: 24623129
Blood. 2012 Oct 11;120(15):3019-29
pubmed: 22932803
Br J Haematol. 1998 Nov;103(2):335-42
pubmed: 9827902
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Front Immunol. 2017 Jan 11;7:690
pubmed: 28123387
J Hematol Oncol. 2018 Mar 15;11(1):39
pubmed: 29544515
Nature. 2017 Dec 7;552(7683):116-120
pubmed: 29186113
Cancer Res. 1993 Oct 15;53(20):5012-7
pubmed: 8402692
Nat Rev Cancer. 2003 Dec;3(12):952-9
pubmed: 14737125
Int J Cancer. 2017 Apr 1;140(7):1609-1619
pubmed: 27914100
Int J Mol Sci. 2020 Jan 24;21(3):
pubmed: 31991626
Clin Cancer Res. 2011 Jun 15;17(12):3884-91
pubmed: 21680544
Nat Rev Cancer. 2015 Aug;15(8):451-2
pubmed: 26422835
Oncotarget. 2016 Feb 9;7(6):7318-28
pubmed: 26802025
Cancer Res. 2015 Sep 1;75(17):3466-78
pubmed: 26113085
React Oxyg Species (Apex). 2018 Mar;5(14):118-125
pubmed: 29780885
Carcinogenesis. 2010 Oct;31(10):1897-902
pubmed: 20688835
Cancer Res. 2012 Nov 15;72(22):5721-32
pubmed: 22986739
Am J Hematol. 2019 May;94(S1):S3-S9
pubmed: 30680780
Mol Ther. 2014 May;22(5):1029-38
pubmed: 24572294
Cancers (Basel). 2020 Mar 13;12(3):
pubmed: 32183192
Methods Mol Biol. 2020;2102:149-160
pubmed: 31989553
Cancer Res. 2012 Jul 1;72(13):3163-74
pubmed: 22570253
Gut. 2018 Oct;67(10):1845-1854
pubmed: 29602780
MAbs. 2018 Nov-Dec;10(8):1301-1311
pubmed: 30204048
Exp Hematol. 2019 Feb;70:31-41.e1
pubmed: 30590092
Blood. 2011 Mar 17;117(11):3076-86
pubmed: 21252091
Blood Adv. 2019 Feb 12;3(3):268-274
pubmed: 30696625
Ann Transl Med. 2019 Dec;7(23):735
pubmed: 32042751
Ann Oncol. 2016 Jul;27(7):1190-8
pubmed: 26912558
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Cancers (Basel). 2019 Nov 15;11(11):
pubmed: 31731753
Urol Res. 1997;25(3):179-82
pubmed: 9228669
Nature. 2005 Aug 4;436(7051):725-30
pubmed: 16079851
Adv Immunol. 2016;130:1-24
pubmed: 26922998
Mol Cancer. 2008 Apr 07;7:29
pubmed: 18394172
Annu Rev Pathol. 2017 Jan 24;12:187-215
pubmed: 27959627
PLoS One. 2016 Sep 23;11(9):e0163521
pubmed: 27662655
Cell. 1987 May 22;49(4):465-75
pubmed: 3032456
J Mammary Gland Biol Neoplasia. 2019 Jun;24(2):149-162
pubmed: 30810966
Oncogene. 2017 May 11;36(19):2637-2642
pubmed: 27797377
Eur J Immunol. 2005 Dec;35(12):3599-609
pubmed: 16304638
Science. 1988 Sep 23;241(4873):1632-9
pubmed: 2971269
Br J Pharmacol. 2013 Jun;169(4):719-35
pubmed: 23488622
J Immunother Cancer. 2019 Feb 8;7(1):37
pubmed: 30736857
Curr Protoc Pharmacol. 2016 Jun 01;73:14.39.1-14.39.20
pubmed: 27248578
Blood. 2012 May 3;119(18):4133-41
pubmed: 22354001
Annu Rev Immunol. 2011;29:235-71
pubmed: 21219185
Blood. 2013 Nov 14;122(20):3461-72
pubmed: 24016461
Cancer Lett. 2013 May 1;331(2):174-82
pubmed: 23321500
J Thorac Oncol. 2018 Mar;13(3):399-412
pubmed: 29233790
Trends Pharmacol Sci. 2016 Mar;37(3):220-230
pubmed: 26705086
Sci Rep. 2019 Jul 23;9(1):10634
pubmed: 31337787
Cell. 2015 Jun 18;161(7):1539-1552
pubmed: 26091037
Int J Cancer. 2017 Feb 1;140(3):662-673
pubmed: 27750381
J Transl Med. 2020 Feb 5;18(1):57
pubmed: 32024545
Blood. 2015 Jul 30;126(5):629-39
pubmed: 26041741
Cancer Chemother Pharmacol. 1997;40(3):209-14
pubmed: 9219503
Mol Ther. 2018 Jun 6;26(6):1423-1434
pubmed: 29735365
Dis Model Mech. 2018 Jan 18;11(1):
pubmed: 29208627
Oncoimmunology. 2014 Jul 03;3(7):e946361
pubmed: 25610731
Cancer Immunol Immunother. 2020 Jun;69(6):1001-1014
pubmed: 32088772
Hum Gene Ther. 2018 May;29(5):534-546
pubmed: 29390873
Hum Gene Ther. 2015 Jul;26(7):432-42
pubmed: 26086867
Toxicol Res. 2014 Mar;30(1):1-5
pubmed: 24795792
Annu Rev Immunol. 1991;9:323-50
pubmed: 1910681
Front Pharmacol. 2018 Mar 20;9:259
pubmed: 29615915
Nat Rev Cancer. 2010 Jul;10(7):470-80
pubmed: 20574449
Cell. 2014 Oct 9;159(2):440-55
pubmed: 25263330
Methods Mol Biol. 2016;1422:297-307
pubmed: 27246042
Eur Surg Res. 2011;47(2):98-107
pubmed: 21720167
Int J Cancer. 2019 Nov 1;145(9):2535-2546
pubmed: 31241175
Methods Mol Biol. 2019;1953:241-252
pubmed: 30912026
Oncol Rep. 2019 Dec;42(6):2183-2195
pubmed: 31578576
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Cell. 2009 Sep 4;138(5):822-9
pubmed: 19737509
Curr Pharm Biotechnol. 2018;19(1):5-18
pubmed: 29667553
Gastroenterology. 2012 Oct;143(4):1095-107.e2
pubmed: 22750462
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13982-7
pubmed: 26508638
Nat Biotechnol. 2015 Apr;33(4):390-394
pubmed: 25690852
Nat Commun. 2019 Dec 5;10(1):5546
pubmed: 31804466
Genes Dev. 2016 Jun 15;30(12):1470-80
pubmed: 27340177
EMBO Mol Med. 2017 Feb;9(2):137-153
pubmed: 28028012
Front Bioeng Biotechnol. 2020 Apr 09;8:322
pubmed: 32328489
Cancer Discov. 2018 Nov;8(11):1358-1365
pubmed: 30309862
J Transl Med. 2014 Apr 29;12:107
pubmed: 24779345
Cancer Immunol Res. 2016 Jun;4(6):498-508
pubmed: 27059623
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Cancer Prev Res (Phila). 2017 Dec;10(12):684-693
pubmed: 29018057
Nature. 1988 Sep 15;335(6187):256-9
pubmed: 2970594
Mol Ther. 2011 Apr;19(4):760-7
pubmed: 21326215
J Immunol. 2010 Feb 15;184(4):1885-96
pubmed: 20089697
Mol Ther. 2014 Jan;22(1):18-27
pubmed: 24048441
Quant Imaging Med Surg. 2015 Oct;5(5):708-29
pubmed: 26682141
J Hematol Oncol. 2017 May 12;10(1):106
pubmed: 28499452
J Immunother. 2019 Feb/Mar;42(2):33-42
pubmed: 30586347
FASEB J. 2018 Mar;32(3):1537-1549
pubmed: 29146734